Amira Announces The Successful Completion Of GLP Toxicity Studies For A Novel DP2 Antagonist

Amira Pharmaceuticals, Inc. announced AM211, Amira’s internally discovered oral drug candidate for the treatment and control of inflammatory and allergic diseases linked to the arachidonic acid pathway, is on target for submission of an IND to the U.S. Food and Drug Administration (FDA) by mid-2009 following the successful completion of Good Laboratory Practices (GLP) toxicity studies.

More: continued here

Filed under: Allergies on January 11th, 2009